Smart Inhalers Market Analysis & Forecast to 2028 by Key Players, Share, Trend, Segmentation The Smart Inhalers Market study focuses major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure. Browse key industry insights spread across 192 pages with 162 market data tables & 14 figures & charts from the report, “Smart Inhalers Market Analysis By Product (Dry Powder Inhaler (DPI)-based Smart Inhalers, Metered Dose Inhaler (MDI)-based Smart Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028” in detail along with the table of contents: https://www.gminsights.com/industry-analysis/smart-inhalers-market Recently, industry players have been working towards developing advanced technologies and entering new markets by forming successful partnerships, which has been favorable for business growth. For instance, in May 2020, Propeller Health, a prominent digital health firm focused on COPD and asthma treatment, acquired 510(k) approval from the U.S. FDA to integrate patients who use the Symbicort Inhaler into its digital health platform. Propeller's platform currently connects to most inhalers used by patients with asthma and COPD, including those made by its competitors GlaxoSmithKline, Boehringer Ingelheim, Orion, and Novartis, along with numerous generic equivalents. This clearance was a crucial step in the company's aim to transform the way patients access preventative care, enable self-management in home settings, and ensure that providers can focus on high-risk patients. The smart inhalers market has been bifurcated in terms of product, disease indication, distribution channel, and region. With respect to product, the market has been divided into MDI-based smart inhalers and DPI-based smart inhalers. The MDI-based smart inhalers segment is anticipated to register a positive CAGR of over 7.7% by 2028 because of the increasing adoption rate of these inhalers due to their many benefits as well as technical advancements in the product. On the basis of disease indication, the market has been segmented into chronic obstructive pulmonary disease (COPD) and asthma. The COPD segment is slated to record a CAGR of approximately 7% through the forecast period owing to rising number of asthma patients. Increasing use of smart inhaler devices to monitor and control effective doses among asthma patients, coupled with surging preference for advanced technologies among patients, is set to fuel segmental growth.
© 2022 Global Market Insights Inc. All Rights Reserved
www.gminsights.com